Sports Kyunghang announcing the actor’s recent diagnosis and current health condition.“As a preemptive measure, Park Seo-joon carried out tests using self-testing kits before moving to all his filming sets,” Awesome ENT wrote, as translated by Soompi. “Before proceeding to his scheduled activity last week, he tested positive using a self-testing kit, so after carrying out a PCR test, he ultimately received a positive test on February 19.”Awesome ENT went on to clarify that the Itaewon Class star had already been triple-vaccinated against the virus prior to his diagnosis, and had halted all his scheduled activities from February 18 as a safety precaution.“[Park Seo-joon] is taking the necessary measures to quarantine and receive treatment in keeping with the guidelines set by government health authorities,” the statement read. “He is currently in the recovery stage and has no special symptoms.” Park is set to star in an upcoming thriller K-drama series titled Gyeongseong Creature as its lead, alongside Han So-hee (My Name) and Wi Ha-joon (Squid Game).
The series is expected to premiere sometime in 2023.He is also slated to appear in the upcoming film The Marvels, which premieres in November this year, becoming the third South Korean actor to join the Marvel Cinematic Universe.
Read more on nme.com
Get the latest stars news and celebrity rumours with exclusive stories, photos, videos and interviews.
Breaking up, scandals, engagements, divorces, gossip – all you need to know about the private lives of your favorite celebs.
Get to know the latest showbiz news along with exclusive interviews and even more. All this is waiting for you on the main page 24 hours a day, 7 days a week! Who, where, when, with whom, how, why and for what!? Stay tuned to know first!
Just follow us daily and we will provide you with the current news from the life of famous stars and celebrities.
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
Address:
Snowland s.r.o.
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
Czech Republic
©2024. All rights reserved.